Cantor Fitzgerald Forecasts Stronger Earnings for Cerus

Cerus Co. (NASDAQ:CERS) – Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Cerus in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now expects that the biotechnology company will post earnings of ($0.11) per share for the year, up from their prior estimate of ($0.12). The consensus estimate for Cerus’ current full-year earnings is ($0.12) per share. Cantor Fitzgerald also issued estimates for Cerus’ FY2025 earnings at ($0.06) EPS.

Separately, Stifel Nicolaus dropped their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th.

Cerus Trading Up 2.2 %

NASDAQ:CERS opened at $1.85 on Thursday. Cerus has a one year low of $1.38 and a one year high of $2.59. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The company’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $1.89. The firm has a market capitalization of $343.57 million, a P/E ratio of -16.82 and a beta of 1.27.

Cerus (NASDAQ:CERS) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $46.02 million for the quarter, compared to analyst estimates of $44.10 million. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%. During the same quarter in the previous year, the firm posted ($0.03) EPS.

Insider Activity

In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the completion of the transaction, the director now directly owns 162,133 shares in the company, valued at $288,596.74. This represents a 10.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cerus

Hedge funds and other institutional investors have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in Cerus during the fourth quarter valued at $29,000. SG Americas Securities LLC increased its stake in Cerus by 84.9% in the 4th quarter. SG Americas Securities LLC now owns 128,836 shares of the biotechnology company’s stock worth $198,000 after buying an additional 59,156 shares during the period. Avanza Fonder AB purchased a new position in Cerus in the 4th quarter worth about $169,000. PCA Investment Advisory Services Inc. purchased a new position in Cerus in the 4th quarter worth about $46,000. Finally, Franklin Resources Inc. increased its stake in Cerus by 13.8% in the 3rd quarter. Franklin Resources Inc. now owns 93,763 shares of the biotechnology company’s stock worth $177,000 after buying an additional 11,338 shares during the period. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.